12:00 PM EST - ProMIS Neurosciences, Inc. : Today commented on the November 6 FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting and its review of Biogen’s Biologics License Application (BLA) for aducanumab for the treatment of Alzheimer’s disease. ProMIS Neurosciences, Inc.
shares T.PMN are trading down $0.02 at $0.13.
